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1. INTRODUCTION
Cancer is the second cause of death worldwide, immediately aftercardiovascular diseases. As reported by the GLOBOCAN (Global
Cancer Statistics), there were 12,7 million cancer cases and 7,6 million
cancer deaths in 2008 and these numbers continue to rise (1). The main
reasons for these unfavorable cancer statistics have been recognised and
include: 1) ageing of the world population, as cancer mostly affects
adults of the advanced age, and 2) an increasing adoption of cancer-
-causing behaviors, due to the processes of modernisation and globali-
sation (1, 2). Related to the latter, domination of chronic noncommu-
nicable diseases, including cardiovascular diseases, cancer, chronic res-
piratory diseases, diabetes and dementia, in health statistics of modern
societies, have been attributed to modern lifestyles, such as increased
consumption of processed foods riched in saturated fats and sugars,
cigarette smoking, sedentary lifestyle and weight gain (3).
In developing countries, on the other hand, perinatal mortality,
infectious diseases and malnutrition, are still at the leading positions of
morbidity and mortality causes, due to poor life conditions, sanitation
and medical care (4). The interesting thing is that the correlation be-
tween the economic development and the shift in a major disease bur-
den, from acute infections to chronic noncommunicable diseases, is not
simple biased, but rather complex-shaped. Namely, as economic de-
velopment occurs, tobacco and alcohol use and obesity increase, fol-
lowed by the burden of chronic diseases in decades later. These negative
trends in health behaviors and subsequently in morbidity and mortality
from chronic diseases start to revert only when very high level of social
and economic development is reached (5). During the period of transi-
tion, chronic diseases do not simple replace acute infections; rather,
there is a double disease burden, having a huge negative impact on the
economies of transitional countries (5, 6). It is not surprisingly then that
in the coming decades, the burden from chronic diseases, including
cancer, is projected to rise, particularly fast in the developing and
transitional countries (6).
In regard to cancer, there are some other important facts. Although
overall cancer incidence rates in developing countries are comparable
to those registred in the developed countries, the cancer mortality
generally exceeds (1). The reason is unfavourable cancer survival rates
in developing countries, due to a late stage at diagnosis and limited
access to timely and standard treatment (1, 7).
Based on these considerations, the greatest opportunity for taking
the control over the growing cancer burden worldwide is likely to lie in
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prevention and early detection of cancer, especially when
organised at a global scale. It is estimated that up to one
third of the cancer burden could be prevented if im-
plemented strategies aimed at reducing the exposure to
cancer risks. Another third of this burden could be cured
if detected and treated cancer early (8). The proclaimed
aims and initiatives for a global action were set up under
some basic documents, such as World Cancer Declara-
tion 2006 (9).
2. CANCER PREVENTION
Important to know, when planning preventive strate-
gies to reduce the burden of chronic noncommunicable
diseases, including cancer, is that there are multiple risk
factors sharing among these diseases (2, 10). Also impor-
tant is to understand that there is a complex chain of
events linking risk factors. In the proximity, there are
more direct causes of the diseases. Factors located further
in the back, act through intermediary mechanisms to
produce these proximal factors. Causally most distal fac-
tors have their background in social conditions and are
hardly recognisable. However, if modified, they are likely
to have strong amplifying influence, by causing multiple
proximal effects (2). Based on these facts, it is not difficult
to realise that, besides individually oriented preventive
measures, there are also population-based strategies (2, 3).
For example, in order to successfully disseminate healthy
diet and regular physical activity patterns among indivi-
duals of high risk groups, policy makers should also im-
plement strategies at the community level, to ensure an
equal access for all population groups to healthy food
choices and opportunities for physical activity (3).
Also important to know, in this issue, is that more than
one third of the world's deaths can be attributed to only a
limited number of risk factors (2, 10). The five top-rank-
ed risks include: high blood pressure, cigarette smoking,
high blood glucose, low physical activity and overweight/
obesity. These risk factors affect countries of all income
groups, high, middle and low. When taking into account
the fact that two leading causes of death worldwide in-
clude cardiovascular diseases and cancers, this is likely to
suggest that avoiding tobacco and obesity, and using
regular physical activity, can provide the greatest poten-
tial to minimise cancer risk (Table 1) (2, 3).
2.1. Infections as a preventable cause
of cancer
Based on estimation, approximately 15% of all cancers
can be attributed to viral infections. At least six viruses
have been recognised as to have a strong oncogenic poten-
tial, including Epstein-Barr virus (EBV), Hepatitis B vi-
rus (HBV), Hepatitis C virus (HCV), several Human
Papillomavirus (HPV) types, Human T-cell Lymphotro-
pic Virus type I (HTLV-I) and Human Immunodeficien-
cy Virus type I (HIV-I) (11). The fact that infected cells may
maintain the state of latency for years before turning on
the oncogenic pathway, may complicate targeting pre-
ventive and therapeutic strategies (12, 13). The beneficial
fact is that knowledge about the ways these infections are
being spreaded on is available and is likely to provide
directions for their prevention. For example, some of these
infections are sexually transmitted, so practicing safe sex
and use of contraception might be an appropriate way of
infection control. Others are associated with using non-
sterilised injection equipment, due to opiates addiction,
thus providing proposals for planning prevention (2, 11).
Another opportunity lies in the development of antivi-
ral vaccines (Table 1) (14). Commercially available HBV
and HPV vaccines are already in use, and the major focus
is now on their delivery, especially to low-income coun-
tries (15, 16). Such strategy is based on estimates that
HBV infection may account for about 60% of the total
liver cancer in developing countries, while only for about
23% in developed countries. For cervical cancer (HPV
infection was proved as a cause), figures show that more
than 85% of all cases and deaths occur in developing
countries (2, 17).
2.2. Industrial carcinogenes and
environmental pollution as a cause of
cancer
The discovery of smoking tobacco as a factor strongly
associated with lung cancer (more than 85% of lung
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TABLE 1
Primary prevention measures (taken before any sign of a disease occures) known to deal with the reduction in total cancer
incidence.
• Implementation of principles of a healthy life-style, mainly by means of a healthy diet – low in saturated fats and carbohydrates
and high in fruit and vegetable, regular physical activity, no smoking, and only moderate alcohol consumtion
• Changes in sexual behaviour (including the number of partners, partners selection, the type of sex involved, knowledge on
infection status of partners, use of barrier contraceptives)
• Immunization against Hepatitis B Virus (HBV) and Human Papilloma Virus (HPV) infection
• Taking the control over occupational hazards
• Avoidance of cancer-causing substances in the global environment and in consumer products
• Avoidance of attentive exposure to sunlight
cancers occur among smokers) has initiated a search for
other external factors that could probable cause cancer
(termed "carcinogenes") (4, 18). Accordingly, at least 150
chemicals and other agents, including ionizing radia-
tion, occupational (workplace) and environmental air-
borne particles, some drugs, as well as foods and other
consumer products, have been listed so far by IARC
(International Agency for Research on Cancer) as poten-
tial carcinogens (Table 1) (2, 18). For example, it is esti-
mated that occupational exposure to microscopic air-
borne particles may account for 8% of lung cancer (2).
The growing number of evidence also shows that long-
term exposure to traffic-related air pollution is the risk
factor which can contribute to overall respiratory and
cardiovascular mortality, including also lung cancer (19).
The encouraging fact is, however, that the majority of
occupational cancers can be prevented, either by imple-
menting safety measures into technology processes, or by
substituting safer materials. In the area of consumer
products, higher level of awareness could be the neces-
sary step before starting transformation towards more
adequate legislation, adversiting and technology innova-
tions (2, 18).
3. EARLY CANCER DETECTION
Results of randomised trials showed that the curability
of cancer is relatively high if it is detected in the early,
localised stage (20, 21). Fundamental thing in early can-
cer detection is availability of effective, low-cost, simple
and safe screening tests. Fortunately, these tests, proved
so far as being feasible for wide implementation, corres-
pond with some of the most frequent cancer sites (Table
2, 3) (2).
Currently available screening tests include: high-qua-
lity mammography (for breast cancer), Pap cytology test
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TABLE 2
Leading cancer incidence and mortality rates, females, for more and less developed areas, world (GLOBOCAN 2008).
Estimated Age-standardized Incidence and Mortality Rates (per 100,000) by Sex, Cancer Site, and Level of Economic Development, 2008
Females
Developed countries Developing countries
Incidence Mortality Incidence Mortality
Breast 66,40 15,30 27,30 10,80
Cervix uteri 9,00 3,20 17,80 9,80
Colon & rectum 24,20 9,70 9,40 5,40
Corpus uteri 12,90 2,40 5,90 1,70
Liver 2,70 2,50 7,60 7,20
Lung & bronchus 18,60 13,60 11,10 9,70
Melanoma of skin 8,60 1,10 0,60 0,30
Ovary 9,40 5,10 5,00 3,10
Pancreas 5,40 5,10 2,10 2,00
Stomach 7,30 4,70 10,00 8,10
Thyroid 9,10 0,40 3,40 0,70
Ali sites* 225,50 87,30 138,00 85,40
TABLE 3
Leading cancer incidence and mortality rates, males, for more and less developed areas, world (GLOBOCAN 2008).
Estimated Age-standardized Incidence and Mortality Rates (per 100,000) by Sex, Cancer Site, and Level of Economic Development, 2008
Males
Developed countries Developing countries
Incidence Mortalitv Incidence Mortalitv
Bladder 16,60 4,60 5,40 2,60
Colon & rectum 37,60 15,10 12,10 6,90
Esophagus 6,50 5,30 11,80 10,10
Liver 8,10 7,20 18,90 17,40
Lung & bronchus 47,40 39,40 27,80 24,60
Pancreas 8,20 7,90 2,70 2,50
Prostate 62,00 10,60 12,00 5,60
Stomach 16,70 10,40 21,10 16,00
Ali sites* 300,10 143,90 160,30 119,30
(for cervical cancer) and testing for occult faecal bleeding
(for colorectal cancer) (22). Because strong evidence are
lacking, the screening of healthy men on prostate cancer
by using prostate-specific antigen (PSA) testing has not
yet been established routinely on a population base. How-
ever, the growing amount of evidence argues toward cost
effectiveness of the systematic use of this test (22, 23, 24).
Another fundamental thing, in this issue, is a need to
checking an apparently healthy population by using
screening tests, that is, before clinical signs of cancer are
detectable, in order to find individuals with the early
cancer or pre-cancer stages (25). In terms of that, the
screening on cancer can be considered as a measure of a
secondary prevention. There are two main approaches
for targeting population: 1) targeting high-risk people (a
lifetime risk of getting a certain type of cancer is at least
20 to 25%), who are most likely to benefit from the
intervention, and 2) targeting risk in the entire popula-
tion, regardless of each individual`s risk and potential
benefit (2).
Based on the growing knowledge and rapid techno-
logy progress, new screening methods tend to replace
some basic ones, such as the case with the convential
FOBT (Faecal Occult Blood Test) and its modifications,
including the Faecal Immunochemical Test (FIT) and
Stool DNA Test (26). Efforts have also been made in
looking for appropriate methods for the early detection of
some other frequent and/or hazardous cancer sites, such
as lung cancer, or pancreatic cancer (27, 28).
3.1. Screening protocols for particular
cancer sites
3.1.1. Breast cancer
Breast cancer is the leading cause of cancer-related
deaths in women worldwide. However, in Western coun-
tries, the mortality trend has been shown to decreasing in
recent years which can be the result of the screening
programs implementation and the improvements in treat-
ment (17). Namely, it is estimated that this cancer can be
cured in over 90% of cases, if diagnosed in an early stage
and adequately treated (22).
Several procedures are used to diagnose breast cancer,
including clinical (breast self-examination and bimanual
palpation peformed by health care professionals), radiolo-
gical (bilateral mammography and ultrasound) and patho-
logical examination (based on the core needle biopsy).
Advanced imaging techniques, such as MRI (magnetic
resonance imaging) and digital mammography, have re-
cently been added, because of high diagnostic sensitivity
of these methods (29). However, mammography is the
only method to date proved as to can reduce mortality
from breast cancer, and any other method can only be
used as a supplement to mammography (29). For read-
ing mammograms, BI-RADS classification (stages 0-5) is
used. Cases suspected on cancer (BI-RADS 4 or 5) are
refered for follow up (30).
Based on the fact that breast cancer is strongly age-
-dependent, screening mammography is generally re-
commended for women 50-69 years of age, with a 1-year,
or 2-year screening interval (22, 21, 26, 29). However, the
decision to screen becomes more and more based on
weighting benefits against costs, especially concerning
consequences such as inconvenience for patients, radia-
tion risk and overdiagnosis (29, 31).
3.1.2. Cervical cancer
Cervical cancer is the third most commonly diagnos-
ed and the fourth leading cause of cancer death in fe-
males worldwide, with more than 85% of all cases and
deaths occuring in developing countries. This disparity is
associated with low level of knowledge about unsafe sex
and with inaccessibility to screening and treatment pro-
grams, for women in developing countries. In developed
countries, the main problem is still insufficient coverage
of women in the generative age with screening (2, 17, 32).
Although cervical cytology, based on Pap smears, re-
mains to be the cornerstone of cervical cancer screening,
this method has rapidly been developing, due to im-
proved understanding of the natural history of the di-
sease and technology innovations (26, 33). Related to
this, it is now well known that a persistent infection with
sexually transmittable human papillomaviruses is res-
ponsible for virtually all cases of cervical cancer. This
evidence has initiated the development of HPV DNA
testing, to support more accurate risk stratification, beyond
the capacity of conventional Papanicolaou smear testing
(26, 33). In addition, primary prevention by prophylactic
vaccination against the HPV types that are causally link-
ed with most cervical cancers in Europe, HPV-16 and
HPV-18, is now commercially available (14). The vaccine
is expected to decrease the number of newly diagnosed
cases by up to 70%. However, as prophylactic vaccination
is performed in young girls, it will take a time until
vaccination provides the visible health gains.
3.1.3. Colorectal cancer
Cancers of the colon and rectum hold the third posi-
tion in frequency worldwide and are also the most com-
mon newly diagnosed cancer in EU (17). In general,
incidence is increasing along with industrialisation and
urbanisation. Five-year survival rates are worse in the
Eastern European countries then in the developed ones
(34% compared to 54%) (17, 34). In past decades, as the
result of the early detection programs implementation,
five-year survival rates in many EU countries show more
favourable trends in all regions of Europe, compared to
as it was before (34).
In most recommendations, the FOBT is used as a
standard screening method and a colonoscopy for fol-
low-up of test-positive cases. The rationale is based on
the fact that a pre-cancer lesion (adenoma), or a colo-
rectal tumour at an early stage, may cause minor bleed-
ing, invisible to the naked eye (35). Experiences gained
so far showed that 3-5% subjects with positive results of
the FOBT can be expected, and 10-15% of them (re-
ferred to colonoscopy) can be expected as diagnosed with
cancer (35, 36, 37).
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Since about 70% of patients are >65 y of age and the
disease is rare under the age of 45, target groups for
screening usually include population aged 50-74y, with
the minimum recommendations for the age range 60-69y
(26, 34). Experiences until now showed that if screening
strategies are implemented as organised programs based
on the screening interval of 1-2 years, it is possible to
reduce mortality rate for 18% – 33% (38).
3.1.4. Prostate cancer
Prostate cancer is one of the three major cancer sites in
men; commonly occures after 50 years of age, with inci-
dence progressively increasing in later decades of life.
Only males with positive family history of a disease are at
a higher risk even in age before 50. Although there are
evidence indicating that population-based screening may
reduce prostate cancer mortality, patients should have an
opportunity to make an informed decision on whether to
be screened or not. This is because of some uncertainties
still being unresolved. Namely, screening increases pro-
state cancer incidence, including also subclinical forms
that will not develop during life, thus leading to unne-
cessary manipulation and overtreating. Long prospective
studies are expected to justify decisions (24, 39).
Screening protocol include digitorectal examination
(DRE) and PSA (prostate-specific-antigen) measuring
in serum, in patients aged =50 years, in those who refer
symptoms of prostatism and urinary tract disorders, or in
those who require screening. The decision on whether or
not to have a prostate biopsy (performed by transrectal
ultrasound, TRUS) should take into account PSA para-
meters, such as free (f) PSA, fPSA/PSA ratio, DRE find-
ings, prostate size, patient age, comorbidities, patient
values and history of previous biopsy (24, 39).
4. EARLY CANCER DETECTION
PROGRAMS
Programs, differently from screening protocols, are
fairly planned in an advance and performed according to
the up to date standards of a medical care, with external
finance assured (Table 4, 5). That means that some degree
of public responsibility, organisation and supervision is
required for screening activities to be qualified as a pro-
gram. Important element is also a cancer surveillance sys-
tem, allowing data collection on cancer statistics and risk
factors burden, as well as a feedback of measures done. In
addition, a public screening policy must be documented
in a law, or regulated in some other official way (32). The
early cancer detection programs even tend to become a
part of more comprehensive national strategies for cancer
control, including also primary prevention and health
promotion, as well as rehabilitation of cured patients,
and palliative care for patients with infaust prognosis (8).
4.1. Situation in EU countries
In the European Union, 2,5 million of people were
diagnosed with cancer in 2008 (17). During the past
decades, cooperation at the EU level showed that it is
possible to add value, beyond the national level, to reduce
cancer burden in Europe. The goal, set under the Com-
mission's "Europe Against Cancer" programs (1987–2000),
was a 15% reduction in cancer mortality by 2000 (25).
Although significant advances have been made, cancer is
still a major public health concern in EU, accounting for
29% (3 out of 10) of deaths in men and 23% (2 out of 10)
of deaths in women (the facts for 2008) (40).
Nowadays, the situation is characterised with sub-
stantial inequalities in cancer control among Member
States. Until 2007, 22 Member States (out of 27) have
adopted policies for implementing population-based
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TABLE 4
Croatian National Program (started in 2006). Recommendations for screening.
CANCER SITE RECOMMENDATIONS
Breast • mammography for women aged 50-69, every two years
• special protocol for women with family history of first-degree relatives with breast cancer, with determined
non-tumour or tumour breast disease and other risks (earlier controls start, more frequent examinations)
Cervix • Pap test for women aged 25-64, every three years
Colon Rectum • Fecal Occult Bleeding Test (FOBT) or Fecal Immunochemical Test (FIT) for persons >50, every three years
• Colonoscopy for persons with positive FOBT results to determine bleeding cause
• Individuals at increased or high risk of colorectal cancer, including persons with history of colorectal
adenoma or cancer, ulcerative colitis, Chronvs disease, family history of polyposis syndromes (FAP, Gardner,
Turcot, Peutz-Jaghers syndrome, familial juvenile polyposis, non-polyposis colon cancer, first-degree relative
with colorectal cancer should be included in early cancer detection program at younger age.
Prostate • digitorectal examination and PSA test once a year for;
– males at increased risk aged 40 years and older
– males with prostatism symptoms aged 50 years and older;
• males aged 50 years and older who request an examination
Health Awereness • persons visiting family physicians should be distributed leaflets and brochures on prevention and early
detection of cancer in the most frequent sites.
screening programs. In 11 of them, nationwide rollout of
population-based programs is completed, in 7 of them, it
is ongoing, and in 4 of them, it is being piloted or plan-
ned (32). In several countries in Europe, however, in-
cluding Finland, Sweden, UK and Netherlands, pro-
grams were performed in a way to give possibilities for
quality and effectiveness evaluation (41).
In order to strengthen efforts by sharing information,
capacity and expertise in cancer prevention and control,
the European Commission has recently proposed the
"European Partnership for Action Against Cancer", for
the period 2009–2013 (42).
4.2. Approaches to increase screening
coverage
One of the main problem, in mass screening pro-
grams, is how to increase the screening rates (coverage).
This is two-sided problem. On the one side, there are
problems of supply (program`s implementation perfor-
mans), including necessary equipment, professionals,
implement of evidence, establishment of the call-recall
system, and strictly managed follow up (screening po-
licy). On the other side, there is the problem of moti-
vation of subjects from the target groups for screening
(patients' compliance with screening). The two key steps of
the motivation process can be recognised: 1) a decision to
enter the screening cycle (up-take) and 2) a decision to
stay in (adherence) (43). Both processes are subjected to
changes by educational and motivational activities. It is
important, then, that these activities precede to and/or
follow mass screening programs implementation, since it
has been recognised that the rate of up-take and adheren-
ce to screening may have a long-term effect on program
effectiveness (43, 44).
In regard to this, media campaigns and promotional
activities are usually organised at the national or the local
community level, initiated by policy-makers, public health
services, health professionals' associations, or non-gover-
mental organisations. These activities have multifaceted
aim to inform the community on: 1) risk factors for the
most frequent cancer sites, 2) early symptoms and signs,
3) early detection methods, and 4) the costs and the
benefits of acceptance of screening (45).
On the other hand, individually-oriented educational
activities, for specific patients' groups or individuals, can
be best effective if performed by primary health care
workers, especially family physicians. In this case, these
activities are transformed into what is termed encourag-
ment and empowerment of patients for screening (46).
4.3. Models to enhance program
performance
There is a general assumption that prevention and
early detection of cancer is insufficiently implemented in
practice of family physicians. In most countries, they are
only partially involved, mainly through opportunistic
screening. That means that subjects are referred by a
physician for screening outside the program supplied by
public services, or only under certain conditions, such as
rural and distant areas (25). Although a central role of
family physicians in implementating such programs has
some advantage compared to the strictly centrally con-
trolled programs, it has been recognised that some tech-
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TABLE 5
Croatian National Program. Program organisation chart
nical and professional support to family physicians are
needed, to allow the program to achieve and maintain
high quality norms (47).
In highly income countries, characterised with long
tradition in organising early cancer detection programs,
expected curing and survival rates have already been
achieved. These results can not be attributed only to a
large number of professionals employed and good tech-
nical facilities, but also to the government officials coor-
dinating the programs and comprehensively performed
and sustainable driven strategies aimed at cutting the
common risks factors burden for the most important
chronic diseases, including cardiovascular diseases, dia-
betes and cancer (41, 48).
In lower income countries, strong orientation towards
primary health care in performing programs of preven-
tion and early detection of cancer, are recommended.
This is based on evidence showing that primary care
resources considerable contribute to reducing the adverse
impact of social inequalities on screening (49).
Based on these facts, it is possible to conclude that the
programs for early cancer detection are best performed if
well organised and coordinated, independently on whether
they are conducted by governmental, or public health
institutiones, or predominantly supplied by family medi-
cine teams.
5. CURRENT TRENDS AND FUTURE
CHALLENGES
5.1. Personalised screening
There is no doubt any more that the early detection of
cancer is effective approach to fighting against cancer.
There are no clear attitudes, however, on which strategy
is more efficient than another, especially in the context of
a real social situation, or within the framework of the
current health care system organisation. Awareness is
increasing that variables such as "a benefit-to-risk" and "a
benefit-to-cost" ratio, or "a quality of life measures", should
also be taken into consideration when planning screen-
ing strategies (2, 50).
In addition, new, more specific screening tests, such as
a digital mammography, or immunochemical tests for
testing on occult faecal bleeding, are now available and
increase our chance to detect cancer early. However, high-
er prices of these tests, compared to conventional ones,
require more specifically elaborated screening strategies,
including a precise definition of who should be included
in screening, by using which tests, and under which
conditions (29, 51, 52). Evidence also suggests that variab-
les such as the patient's context, including co-morbid
health disorders and patient's values, are to be taken into
account (29).
5.2. Cancer risk prediction models
The average risk of getting a cancer (for a 5-years, or a
10-years time period, or expressed as a lifetime risk) are
estimated on the basis of the incidence data for the popu-
lation. Many factors that can change these estimates to
the higher or to the lower, for some of the most common
cancers sites, have been identified. Besides classical can-
cer-related risk factors, some biochemical and molecular
biomarkers and information on a personal genome ana-
lysis, have recently been added. Knowledge on this issue
allows personalisation of risk assessments, based on the
estimates such as the score charts, or mathematical risk
prediction models, which can help physicians and policy-
makers to more accurately identify individuals who might
benefit from screening (53, 54, 55).
5.3. Genetic risk estimates
Two Mendelian genetic tests have been established so
far and are expected to improve the cancer risk assess-
ment. These tests include 1) BRCA1 and BRCA2 – highly
penetrant breast and ovarian cancer predisposition genes,
and 2) the mismatch repair (MMR) genes – carriers of
which have a high risk of the hereditary colorectal cancer
and/or endometrial cancer (56, 57).
The dominant problem, when trying to implement
these tests into routine practice, is a lack of the clinical
assessments of genetic risk estimates. For example, is
there an added value of testing on BRCA 1/2 genes in
women with a positive family history of breast cancer,
beyond the standard screening with mammography, es-
pecially when taking into account that familial suscepti-
bility to breast cancer accounts for less than 25% of all
cases? Another concern includes low level of knowledge
on variation in penetrance and expression of cancer-
-prone genes. In addition, evidence is insufficient of how
a genetic counseling might have an impact on the ethical
issues (57, 58).
5.4. Genomics and proteomics
The rapid progress in biotechnology has been expect-
ed to provide huge benefits in prevention and early detec-
tion of chronic noncommunicable diseases, notably can-
cer, by implementing genomics, proteomics and other
-omics techniques in practice. The main principle these
techniques relies on, is a possibility to identify subjects at
an early clinical or subclinical stage of a disease develop-
ment, by obtaining the whole-genome sequencing (ge-
nomics), or by characterising the protein and peptide
profiles of various biological fluids or tissues (proteo-
mics) (59, 60, 61).
The problem is that these techniques are rapidly emerg-
ing, far more than their clinical utility can be evaluated.
Therefore, there is no clear understanding yet, of what
would be real expectations of implementing these tech-
niques in practice, and what are the obstacles that should
be overcome (61, 62).
5.5. The chronic care model
Improvements in the early detection, diagnosis and
treatment of cancer enable people with cancer living
longer and managing their cancers as a chronic illness.
This consideres a long-term surveillance, including pre-
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vention, early detection, diagnosis, treatment, long-term
care after the treatment and survivorship.
Demands are predominantly put on patients and their
families, in managing care on their own, and on family
physicians, in providing them education and support, as
well as a follow up (63).
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